Investigational Drug Beats Clopidogrel At Stopping Stent Thrombosis In Trial
This article was originally published in The Gray Sheet
Executive Summary
Stent recipients taking Eli Lilly's prasugrel have fewer ischemic outcomes, including stent thrombosis, than those taking clopidogrel regardless of stent type, according to a subanalysis of the TRITON-TIMI 38 trial presented March 29 at the American College of Cardiology conference in Chicago